Hidroxicarbamida Hikma (Hydroxycarbamide)

Hidroxicarbamida Hikma is indicated for several hematologic and oncologic conditions where reduction of abnormal cell proliferation is required.

• Sickle cell disease (to reduce vaso‑occlusive crises)
• Polycythemia vera (to control elevated red blood cell mass)
• Essential thrombocythemia (to lower platelet counts)
• Chronic myelogenous leukemia (as part of disease‑modifying therapy)
• Melanoma (in selected cases as adjunctive treatment)
• Myelodysplastic syndromes (for patients with high‑risk disease)

• Hydroxycarbamide exerts its antineoplastic effect by binding to the M2 subunit of ribonucleotide reductase, the enzyme responsible for converting ribonucleotides to deoxyribonucleotides. Inhibition of this enzyme lowers intracellular deoxyribonucleotide pools, which slows DNA synthesis and limits the replication of rapidly dividing cells, including abnormal hematopoietic and malignant cells. The resulting cytoreduction underlies its therapeutic benefit in myeloproliferative disorders and sickle cell disease.

Adverse reactions to Hidroxicarbamida Hikma vary in frequency and severity.

Common

• Nausea or vomiting
• Abdominal pain or dyspepsia
• Loss of appetite
• Mild fatigue
• Low white blood cell count (leukopenia)
• Elevated liver enzymes

Serious

• Severe neutropenia or agranulocytosis
• Acute hemolytic crisis (especially in G6PD deficiency)
• Renal impairment or failure
• Severe skin reactions such as Stevens‑Johnson syndrome
• Life‑threatening infection due to immunosuppression

Before starting Hidroxicarbamida Hikma, clinicians should evaluate several safety considerations to minimize risk.

• Assess baseline complete blood count and liver and kidney function.
• Avoid use in pregnant women; the drug is classified as pregnancy category D.
• Use only when the benefits outweigh risks in patients with known G6PD deficiency.
• Monitor blood counts regularly during therapy to detect cytopenias early.
• Counsel patients on signs of infection, bleeding, or severe fatigue.
• Adjust dose or discontinue if significant organ toxicity develops.
• Ensure adequate hydration to reduce risk of renal complications.

Hydroxycarbamide can interact with other medicines, affecting its efficacy or safety profile.

Avoid

• Concurrent use with other myelosuppressive agents (e.g., chemotherapy, azathioprine) that may exacerbate bone‑marrow suppression.
• Live vaccines, because immunosuppression can increase risk of infection.
• Strong CYP2C9 inhibitors (e.g., fluconazole) that may raise hydroxycarbamide levels.

Use with caution

• Allopurinol or febuxostat, which may increase risk of hypersensitivity reactions.
• NSAIDs, as they can worsen gastrointestinal irritation.
• Anticoagulants (e.g., warfarin), because altered platelet counts may affect bleeding risk.
• Antiretroviral drugs metabolized by similar pathways, requiring monitoring.